MapLight Therapeutics (MPLT) Fundamental Analysis: Revenue, Earnings & Valuation

3.35 / 10

Netural

Fundamental analysis rates MPLT as neutral (3.4/10). Strengths include accounts receivable turnover and interest coverage, while weaknesses are income‑tax ratio, fixed‑asset turnover and overall profitability. The profile suggests limited upside without operational improvements.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight43.56%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight2.31%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-2.47%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-2.45%

1M Return-0.65%

PB-ROE

Value1.38

Score2/3

Weight48.84%

1M Return8.98%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight-2.24%

1M Return-0.59%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-4.59%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-2.76%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-2.71%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight22.52%

1M Return4.88%

Is MPLT undervalued or overvalued?

MPLT scores 3.35/10 on fundamentals and holds a Fair valuation at present. Backed by its -56.19% ROE, 0.00% net margin, -4.88 P/E ratio, 1.72 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.